Hybribio Biotech (300639) Subsidiary Secures Expanded Medical Device Production License Valid Until 2029

Deep News

Nov 27

On November 27, Guangdong Hybribio Biotech Co., Ltd. (300639) announced that its wholly-owned subsidiary, Chaozhou Hybribio Biochemical Co., Ltd., has obtained an updated Medical Device Production License issued by the Guangdong Medical Products Administration.

The license modification primarily expands the production scope to include: - Class III 6840 in vitro diagnostic reagents - Class II 18 obstetrics/gynecology, assisted reproductive, and contraceptive devices - Class II 22 clinical laboratory instruments The license, numbered Yue-SFDA-MDP-20041040, remains valid until January 8, 2029.

For the first three quarters of 2025, Hybribio Biotech reported revenue of RMB 486 million with a net loss attributable to shareholders of RMB 128 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1142145081"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142145081\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142145081?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142145081","market":"hk","top_or_hot":-1,"title":"Hybribio Biotech (300639) Subsidiary Secures Expanded Medical Device Production License Valid Until 2029","media":"Deep News","content":"<p>On November 27, Guangdong Hybribio Biotech Co., Ltd. (300639) announced that its wholly-owned subsidiary, Chaozhou Hybribio Biochemical Co., Ltd., has obtained an updated Medical Device Production License issued by the Guangdong Medical Products Administration.</p>\n<p>The license modification primarily expands the production scope to include:  \n- Class III 6840 in vitro diagnostic reagents  \n- Class II 18 obstetrics/gynecology, assisted reproductive, and contraceptive devices  \n- Class II 22 clinical laboratory instruments  \nThe license, numbered Yue-SFDA-MDP-20041040, remains valid until January 8, 2029.</p>\n<p>For the first three quarters of 2025, Hybribio Biotech reported revenue of RMB 486 million with a net loss attributable to shareholders of RMB 128 million.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hybribio Biotech (300639) Subsidiary Secures Expanded Medical Device Production License Valid Until 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHybribio Biotech (300639) Subsidiary Secures Expanded Medical Device Production License Valid Until 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-11-27 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On November 27, Guangdong Hybribio Biotech Co., Ltd. (300639) announced that its wholly-owned subsidiary, Chaozhou Hybribio Biochemical Co., Ltd., has obtained an updated Medical Device Production License issued by the Guangdong Medical Products Administration.</p>\n<p>The license modification primarily expands the production scope to include:  \n- Class III 6840 in vitro diagnostic reagents  \n- Class II 18 obstetrics/gynecology, assisted reproductive, and contraceptive devices  \n- Class II 22 clinical laboratory instruments  \nThe license, numbered Yue-SFDA-MDP-20041040, remains valid until January 8, 2029.</p>\n<p>For the first three quarters of 2025, Hybribio Biotech reported revenue of RMB 486 million with a net loss attributable to shareholders of RMB 128 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300639","symbol_name":"凯普生物","start_time":0,"source_url":"","article_id":"1142145081","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142145081","pubTimestamp":1764249634,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On November 27, Guangdong Hybribio Biotech Co., Ltd. (300639) announced that its wholly-owned subsidiary, Chaozhou Hybribio Biochemical Co., Ltd., has obtained an updated Medical Device Production...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159883":"医疗器械","300639":"凯普生物","BK1574":"生物医药B类股","BK0046":"生物疫苗","BK0042":"基因检测","BK1583":"高瓴概念","09996":"沛嘉医疗-B","BK0239":"医药制造","BK1100":"医疗保健设备","BK0132":"高送转概念","09997":"康基医疗","BK1222":"医疗保健用品"},"translate_title":"海博生物(300639)子公司获得有效期至2029年的扩大医疗器械生产许可证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159883":1,"300639":1,"09996":1,"09997":1},"content_text":"On November 27, Guangdong Hybribio Biotech Co., Ltd. (300639) announced that its wholly-owned subsidiary, Chaozhou Hybribio Biochemical Co., Ltd., has obtained an updated Medical Device Production License issued by the Guangdong Medical Products Administration.\nThe license modification primarily expands the production scope to include:  \n- Class III 6840 in vitro diagnostic reagents  \n- Class II 18 obstetrics/gynecology, assisted reproductive, and contraceptive devices  \n- Class II 22 clinical laboratory instruments  \nThe license, numbered Yue-SFDA-MDP-20041040, remains valid until January 8, 2029.\nFor the first three quarters of 2025, Hybribio Biotech reported revenue of RMB 486 million with a net loss attributable to shareholders of RMB 128 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}